The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting

13 Oct 2016

The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at ANESTHESIOLOGY® 2016, the annual meeting of the American Society of Anesthesiologists (ASA), being held at the McCormick Place in Chicago from October 22-26, 2016 and at the International Society for Anaesthetic Pharmacology 25th Annual Meeting (ISAP) taking place at the Hyatt Regency Chicago on October 21, 2016.

Investigators will present data from the MDCO-700 Phase I clinical program and preclinical animal studies evaluating infusion optimization, safety, tolerability and pharmacokinetic and pharmacodynamic parameters at both meetings in the form of oral and poster presentations.

 
   

Details of ASA presentations are provided below:

Date   Time   Product   Event   Place

SATURDAY
October 22

  10:30am-11am   MDCO-700 (ABP-700)  

Session: Poster Presentations:
Anesthetic Action and Biochemistry


Effect on ECG Parameters of ABP-700 Infusions in
Combination With Opiates Targeting Sedation in Man

 

Lead author: Peter Meyer, University Medical Center Groningen

 

Hall F-Foyer
Area B
(Monitor 07, presentation #A1034)

SATURDAY
October 22

  10:30am -12pm   MDCO-700 (ABP-700)  

Session: Anesthetic Action and Biochemistry


The Novel Soft-Etomidate Analogue ABP-700
Increases Seizure Threshold in Rodents


Lead author: Dario Lehoux, The Medicines Company

 

Convention Center Room:
W476 (Oral presentation #A1106)

WEDNESDAY
October 26

  8:00am-9:30am   MDCO-700 (ABP-700)  

Session: Drug Disposition, Metabolism and Elimination


A PK-PD Model for the Novel Positive
Allosteric GABA Receptor Modulator ABP-700


Lead author: Douglas Eleveld, University
Medical Center Groningen

 

Convention Center Room:
W474b (Oral presentation #A5009)

 
   

Details of ISAP presentations are provided below:

Date

 

Time

 

Product

 

Event

 

Place

FRIDAY
October 21

  9:00am   MDCO-700 (ABP-700)  

Session: Poster Presentations


Effect on ECG Parameters of ABP-700 Infusions in
Combination With Opiates Targeting Sedation in Man


Lead author: Peter Meyer, University Medical
Center Groningen

 

Hyatt Regency Chicago
(Room #TBD)

FRIDAY
October 21

  9:00am   MDCO-700 (ABP-700)  

Session: Poster Presentation


A Phase 1 Dose Optimization Study of ABP-700
with Opiates and/or Midazolam Targeting
Induction of General Anesthesia (Preliminary Results)


Lead author: Sascha Meyer, University Medical
Center Groningen

 

Hyatt Regency Chicago
(Room #TBD)

     

About MDCO-700

MDCO-700 (formerly, ABP-700), an investigational product not approved for commercial use in any market, is a novel, positive allosteric modulator of the GABA-A receptor currently being developed for the induction of general anesthesia and procedural sedation. MDCO-700 is from a family of compounds invented by Dr. Douglas Raines at the Massachusetts General Hospital.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose—to save lives, alleviate suffering and contribute to the economics of healthcare. The Company's mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.

Forward Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," "expects," “views” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the clinical trials for our product candidates, including MDCO-700, will advance in the clinical process on a timely basis, or at all, or succeed in achieving their specified endpoints; whether the Company is able to disclose clinical trial results on a timely basis; whether physicians, patients and other key decision makers will accept clinical trial results; whether the Company will make regulatory submissions for its product candidates on a timely basis, or at all; whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis, or at all; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2016 , which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.


Contacts

Media
Russo Partners
Matt Middleman, M.D., 212-845-4272
matt.middleman@russopartnersllc.com
or
Investors
The Medicines Company
Krishna Gorti, M.D., 973-290-6122
Vice President, Investor Relations
krishna.gorti@themedco.com

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com